Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis

Full text
Author(s):
Mello-Bosnic, Claudia [1] ; Gimenes, Alexandre Dantas [2] ; Oliani, Sonia Maria [1] ; Gil, Cristiane Damas [1, 2]
Total Authors: 4
Affiliation:
[1] UNESP Univ Estadual Paulista, Programa Posgrad Biociencias, Inst Biociencias Letras & Ciencias Exatas, Sao Jose Do Rio Preto, SP - Brazil
[2] UNIFESP Univ Fed Sao Paulo, Dept Morfol & Genet, Rua Botucatu 740, Ed Lemos Torres 3 Andar, BR-04023900 Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: European Journal of Pharmacology; v. 833, p. 124-130, AUG 15 2018.
Web of Science Citations: 1
Abstract

Galectin-1 (Gal-1) is a beta-galactoside-binding protein with diverse biological activities in the pathogenesis of inflammation, however the mechanisms by which Gal-1 modulates cellular responses in allergic inflammatory processes have not been fully determined. In this study, we evaluated the therapeutic potential of Gal-1 eye drops in an experimental model of conjunctivitis. Wistar rats received a topical application of compound (C)48/80 (100 mg/ml) into right eyes and a drop of vehicle into the contralateral eye. Another group of rats received Gal-1 (0.3 or 3 mu g/eye) or sodium cromoglycate (SCG; 40 mg/ml) in both eyes and, after 15 min, right eye was challenged with C48/80. Conjunctivitis-induced by C48/80 was characterized by severe eyelid oedema and tearing, but clinical signs were ameliorated by eye drop doses of both Gal-1 (0.3/3 mu g) and SCG. As expected, an increased proportion of degranulated mast cells (62%, P < 0.01) and lower histamine levels were observed after 6 h of C48/80 challenge, compared to control (32%). This effect was abrogated by Gal-1 and SCG, which reduced mast cell degranulation (31-36%), eosinophil migration and eosinophil peroxidase levels in the eyes. Gal-1 (3 mu g) and SCG treatments also decreased IL-4 levels, as well as activation of mitogen activated protein kinases compared to untreated C48/80 eyes. Our findings suggest that Gal-1 eye drops represent a new therapeutic strategy for ocular allergic inflammation. (AU)

FAPESP's process: 15/09858-3 - Mechanisms of action of the galectin-1 and -3 proteins in the allergic inflammation: Study in in vivo and in vitro experimental models and in allergic patients
Grantee:Cristiane Damas Gil
Support type: Regular Research Grants
FAPESP's process: 16/02012-4 - Evaluation of the immunomodulatory activity of annexin A1 protein in the regulation of inflammatory disorders of the gastrointestinal system: studies in vivo and in vitro experimental models
Grantee:Sonia Maria Oliani
Support type: Regular Research Grants